After graduating from Pavia (Italy) medical school in 2015 with a thesis in Pediatric Hematology/Oncology, Dr. Gurnari completed his training in Hematology at the University of Rome, Tor Vergata. He then decided to continue his education at Tor Vergata, and he completed a Ph.D program in “Immunology, Molecular Medicine and Applied Biotechnology”. Simultaneously, Dr. Gurnari has been working since 2019 at the Department of Translational Hematology and Oncology Research of Cleveland Clinic (USA) focusing on the genomics of bone marrow failure disorders and myeloid neoplasia. Currently, Dr. Gurnari is an Assistant Professor of Hematology at University of Rome Tor Vergata.

His clinical and translational research expertise encompasses myeloid malignancies with a special focus on acute promyelocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia as well as bone marrow failure syndromes and germline predisposition. Topics of his interest are particularly DDX41-mutant myeloid neoplasia and VEXAS syndrome. Dr. Gurnari is a member of the European Hematology Association (EHA) for which serves as a Mentor of the Classical Master Class Program, of the European Society for Blood and Marrow Transplantation (EBMT), for which he serves as vice-chair of the MDS subcommittee of CMWP. He is also a member of other national and international societies such as the Italian Hematology Association and the International Paroxysmal Nocturnal Hemoglobinuria Interest Group.

In these years, Dr. Gurnari has been awarded several international prizes such as the Tito Bastianello Young Investigator Award in MDS research and the ASH-IPIG Award for PNH research twice, the Under40 in Hematology Italian award and the NaNa ETS prize at SIES 2024 in Florence. This last prize will be instrumental to continue his work in myeloid malignancies, particularly to shed light on mechanisms of ontogenesis of leukemia from prior bone marrow failure syndromes and germline predisposition.